Recent clinical trials have demonstrated that sodium–glucose cotransporter-2 (SGLT2) inhibition may improve cardiovascular and renal outcomes in type 2 diabetes [1–3], probably via lowering blood pressure and restoring tubuloglomerular feedback [4]. Here, SLC5A2 is linked to type 2 diabetes mellitus.